Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rybak

Showing results (81-90 of 531) with videos related to

Pageof 54
Sort By:
Antimicrobial Agents and Chemotherapy|May 1, 1996
Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection modelD M Cappelletty, M J Rybak
Pharmacotherapy|March 16, 2005
Community-associated methicillin-resistant Staphylococcus aureus: a reviewMichael J Rybak, Kerry L LaPlante
Diagnostic Microbiology and Infectious Disease|October 12, 2004
Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecyclineKerry L LaPlante, Michael J Rybak
Expert Opinion on Emerging Drugs|July 2, 2005
Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteriaG W Kaatz, M J Rybak
Drug Intelligence & Clinical Pharmacy|September 1, 1982
Antimicrobial susceptibility testsS A Hunt, M J Rybak
Clinical Pharmacy|November 1, 1984
Antihypertensive agents and hyperlipidemiaL M Gutschi, M J Rybak
Pharmacotherapy|March 26, 2010
Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogensMolly E Steed, Michael J Rybak
Antimicrobial Agents and Chemotherapy|May 18, 2011
Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic modelMolly Steed, Celine Vidaillac, Michael J Rybak
Wiadomosci Parazytologiczne|August 4, 2006
Glossiphoniidae Vaillant, 1850 (Hirudinea) of Poland--systematics and perspectives of studiesA Bielecki, J Rybak, M Lukowiak-Bielecka
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 22, 2022
Reply to Scheetz et alSara Alosaimy, Michael J Rybak, George Sakoulas
Pageof 54

Showing results (81-90 of 531) with videos related to

Sort By:
Pageof 54
Antimicrobial Agents and Chemotherapy|May 1, 1996
Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection modelD M Cappelletty, M J Rybak
Pharmacotherapy|March 16, 2005
Community-associated methicillin-resistant Staphylococcus aureus: a reviewMichael J Rybak, Kerry L LaPlante
Diagnostic Microbiology and Infectious Disease|October 12, 2004
Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecyclineKerry L LaPlante, Michael J Rybak
Expert Opinion on Emerging Drugs|July 2, 2005
Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteriaG W Kaatz, M J Rybak
Drug Intelligence & Clinical Pharmacy|September 1, 1982
Antimicrobial susceptibility testsS A Hunt, M J Rybak
Clinical Pharmacy|November 1, 1984
Antihypertensive agents and hyperlipidemiaL M Gutschi, M J Rybak
Pharmacotherapy|March 26, 2010
Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogensMolly E Steed, Michael J Rybak
Antimicrobial Agents and Chemotherapy|May 18, 2011
Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic modelMolly Steed, Celine Vidaillac, Michael J Rybak
Wiadomosci Parazytologiczne|August 4, 2006
Glossiphoniidae Vaillant, 1850 (Hirudinea) of Poland--systematics and perspectives of studiesA Bielecki, J Rybak, M Lukowiak-Bielecka
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 22, 2022
Reply to Scheetz et alSara Alosaimy, Michael J Rybak, George Sakoulas
Pageof 54